23 June 2008: The General Meeting resolved on June 18, 2008, that an option scheme for employees in the company for up to 3 770 000 new shares may be established with a strike price of NOK 2.00, which is the same share price as the subscription price in the upcoming rights issue.

The Board has now granted options for 3 770 000 shares with a strike price of NOK 2.00.  All 36 employees participate in the new option program. Primary insiders in the company have been granted a total of 2.263.296 (60%) options as showed in the table below:

Number of options
Name
Owned shares

Berg, Monica
  28.136
0

Engen, Turid
150.000
0

Flo, Elin Berge
30.646
1.000

Holmberg, Anders
100.000
734.655

Hornes, Erik
500.000
46.155

Kjelby, Stein Rune
54.514
0

Kvåle, Tone
300.000
0

Murphy, Nancy
300.000
0

Strømme, Dagfinn
150.000
10.678

Wigstøl, Mårten
500.000
71.055

Wikshåland, Åse
150.000
10.389

The following primary insiders also participate in the underwriting syndicate related to the upcoming rights issue:

Dagfinn Øgreid  (500.000 shares), Mårten Wigstøl (125.000 shares),
Tone Kvåle (50.000 shares), Erik Hornes (25.000 shares), Åse
Wikshåland (32.500 shares), Turid Engen (7.500 shares), Anders
Holmberg (25.000 shares) and Dagfinn Strømme (25.000 shares).

Contact: CEO Mårten Wigstøl               Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Link to the Notice on Oslo Stock Exchange's Newsweb

Link to the Notice in Norwegian